VYNT Stock Overview
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Vyant Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.19 |
| 52 Week High | US$1.58 |
| 52 Week Low | US$0.14 |
| Beta | 0.56 |
| 1 Month Change | 9.30% |
| 3 Month Change | 14.12% |
| 1 Year Change | -72.38% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.19% |
Recent News & Updates
Shareholder Returns
| VYNT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.5% | -3.9% | -3.1% |
| 1Y | -72.4% | -1.8% | 20.9% |
Return vs Industry: VYNT underperformed the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: VYNT underperformed the US Market which returned 24.3% over the past year.
Price Volatility
| VYNT volatility | |
|---|---|
| VYNT Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VYNT's share price has been volatile over the past 3 months.
Volatility Over Time: VYNT's weekly volatility has decreased from 19% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Andy LaFrence | www.vyantbio.com |
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson’s disease (PD).
Vyant Bio, Inc. Fundamentals Summary
| VYNT fundamental statistics | |
|---|---|
| Market cap | US$1.14m |
| Earnings (TTM) | -US$13.03m |
| Revenue (TTM) | US$397.00k |
3.1x
P/S Ratio-0.1x
P/E RatioIs VYNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VYNT income statement (TTM) | |
|---|---|
| Revenue | US$397.00k |
| Cost of Revenue | US$736.00k |
| Gross Profit | -US$339.00k |
| Other Expenses | US$12.69m |
| Earnings | -US$13.03m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.06 |
| Gross Margin | -85.39% |
| Net Profit Margin | -3,281.86% |
| Debt/Equity Ratio | 1.3% |
How did VYNT perform over the long term?
See historical performance and comparison